5.52
price down icon2.30%   -0.13
pre-market  Pre-market:  5.58   0.06   +1.09%
loading
Recursion Pharmaceuticals Inc stock is traded at $5.52, with a volume of 43.10M. It is down -2.30% in the last 24 hours and up +13.11% over the past month. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$5.65
Open:
$5.7
24h Volume:
43.10M
Relative Volume:
1.14
Market Cap:
$2.36B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-3.5613
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
-8.61%
1M Performance:
+13.11%
6M Performance:
-1.25%
1Y Performance:
-12.66%
1-Day Range:
Value
$5.41
$5.7356
1-Week Range:
Value
$5.41
$6.50
52-Week Range:
Value
$3.79
$12.36

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Name
Name
Recursion Pharmaceuticals Inc
Name
Phone
(385) 269-0203
Name
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Name
Employee
800
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
RXRX's Discussions on Twitter

Compare RXRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RXRX
Recursion Pharmaceuticals Inc
5.52 2.47B 64.60M -377.75M -335.64M -1.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
425.57 107.66B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
651.80 68.74B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.04 58.93B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
818.50 50.51B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
189.60 41.29B 447.02M -1.18B -868.57M -6.1812

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-03-25 Resumed Morgan Stanley Equal-Weight
May-22-23 Initiated Morgan Stanley Equal-Weight
Mar-16-23 Initiated Needham Buy
Sep-16-22 Initiated KeyBanc Capital Markets Overweight
Apr-18-22 Downgrade BofA Securities Buy → Neutral
Mar-04-22 Downgrade SVB Leerink Outperform → Mkt Perform
Sep-21-21 Initiated Berenberg Buy
May-11-21 Initiated BofA Securities Buy
May-11-21 Initiated Goldman Neutral
May-11-21 Initiated JP Morgan Neutral
May-11-21 Initiated KeyBanc Capital Markets Overweight
May-11-21 Initiated SVB Leerink Outperform
View All

Recursion Pharmaceuticals Inc Stock (RXRX) Latest News

pulisher
Nov 02, 2025

Biotech Stocks To Add to Your WatchlistOctober 30th - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Top Biotech Stocks To Follow TodayNovember 1st - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Is it time to cut losses on Recursion Pharmaceuticals Inc.Quarterly Market Review & Real-Time Volume Trigger Notifications - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Can Recursion Pharmaceuticals Inc. stock hit record highs againStock Surge & Real-Time Market Sentiment Alerts - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in Shares Following Exscientia Merger - CoinCentral

Nov 02, 2025
pulisher
Nov 01, 2025

Is Recursion Pharmaceuticals Inc. stock poised for growthJuly 2025 Analyst Calls & Verified Stock Trade Ideas - newser.com

Nov 01, 2025
pulisher
Nov 01, 2025

Top Biotech Stocks To Keep An Eye OnOctober 28th - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Best Biotech Stocks To Follow TodayOctober 31st - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Partnerships - Quiver Quantitative

Nov 01, 2025
pulisher
Nov 01, 2025

Will Recursion Pharmaceuticals Inc. stock maintain growth storyPortfolio Performance Report & Low Drawdown Momentum Trade Ideas - newser.com

Nov 01, 2025
pulisher
Oct 31, 2025

Signal strength of Recursion Pharmaceuticals Inc. stock in tech scannersGlobal Markets & Free High Return Stock Watch Alerts - newser.com

Oct 31, 2025
pulisher
Oct 31, 2025

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? - The Globe and Mail

Oct 31, 2025
pulisher
Oct 31, 2025

How to interpret RSI for Recursion Pharmaceuticals Inc. stockShare Buyback & AI Powered Market Entry Strategies - newser.com

Oct 31, 2025
pulisher
Oct 31, 2025

Has Recursion Pharmaceuticals Inc. formed a bullish divergenceVolume Spike & Real-Time Price Movement Reports - newser.com

Oct 31, 2025
pulisher
Oct 30, 2025

BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia - Fierce Biotech

Oct 30, 2025
pulisher
Oct 30, 2025

Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline - sharewise.com

Oct 30, 2025
pulisher
Oct 30, 2025

How Recursion Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 PreEarnings & Community Shared Stock Ideas - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

Recursion Pharmaceuticals Incannounces Roche's exercise of option for Microglia MapSEC filing - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Roche Exercises Option with Recursion Pharmaceuticals - TipRanks

Oct 29, 2025
pulisher
Oct 29, 2025

Recursion Pharmaceuticals Announces Roche's Option Exercise - TradingView

Oct 29, 2025
pulisher
Oct 29, 2025

Published on: 2025-10-29 07:02:21 - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Recursion Pharmaceuticals (RXRX) to Release Quarterly Earnings on Wednesday - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Is Hindustan Media Ventures Limited Stock Poised for a Breakout in YEARVolume Weighted Average Price & Master Stock Selection - earlytimes.in

Oct 29, 2025
pulisher
Oct 28, 2025

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - sharewise.com

Oct 28, 2025
pulisher
Oct 28, 2025

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

Recursion Pharmaceuticals, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo

Oct 28, 2025
pulisher
Oct 28, 2025

Recursion Pharmaceuticals (RXRX): Exploring Valuation as AI Expansion, Key Merger, and Clinical Progress Boost Interest - simplywall.st

Oct 28, 2025
pulisher
Oct 28, 2025

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th - MarketScreener

Oct 28, 2025
pulisher
Oct 28, 2025

Recursion (NASDAQ: RXRX) to host Nov 5 (L)earnings call at 8:00 am ET, livestreamed - Stock Titan

Oct 28, 2025
pulisher
Oct 28, 2025

How Recursion Pharmaceuticals Inc. stock valuations compare to rivalsJuly 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Holdings in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

Sumitomo Mitsui Trust Group Inc. Reduces Stock Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

Will Recursion Pharmaceuticals Inc. stock benefit from sector rotationJuly 2025 Setups & Smart Investment Allocation Tips - fcp.pa.gov.br

Oct 28, 2025
pulisher
Oct 28, 2025

Recursion Pharmaceuticals Inc. stock volume spike explainedJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

When is the best time to exit Recursion Pharmaceuticals Inc.2025 Sector Review & Daily Oversold Bounce Ideas - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is Recursion Pharmaceuticals Inc. stock a top momentum play2025 Big Picture & Capital Protection Trade Alerts - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 27, 2025

Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares - MSN

Oct 27, 2025

Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$37.54
price up icon 1.62%
$93.48
price up icon 0.96%
$28.61
price down icon 0.21%
$103.91
price down icon 0.73%
biotechnology ONC
$310.48
price up icon 0.73%
$189.60
price down icon 2.38%
Cap:     |  Volume (24h):